Genentech, Inc.

F. Hoffmann-la Roche Ag

Ideaya Biosciences, Inc.

Mark Lackner

Guy L Cavet

Lukas C Amler

Carol O'Brien

Ajay Pandita

Jo-Anne Hongo

Bonnee Rubinfeld

Rajesh Vij

Elizabeth Punnoose

Yulei Wang

Walter Christian Darbonne

Zineb Mounir

Siminder Atwal

Daniel Maslyar

Eric Humke

Carol O'BRIEN

The present invention relates to methods and kits or articles of manufacture related thereto that may find use, inter alia, in assessing responsiveness of cancers to MUC16 antagonists by monitoring HE4 expression. In some embodiments, the methods include measuring the level of expression of HE4 in a sample from a subject; comparing the level of expression of HE4 in the sample with the level of expression of HE4 in a sample previously obtained from the subject; and, optionally, administering to the subject a therapeutically effective amount of a MUC16 antagonist.

Use of human epididymis protein 4 (HE4) for assessing responsiveness of MUC 16-positive cancer treatment

Methods and compositions are provided to determine if a cancer is resistant to treatment with anti-mitotic agents, including treatment with T-DM1. The methods relate to determining if the ABCC3 gene is amplified and/or overexpressed in the cancer.

Genetic variations associated with drug resistance

The invention provides methods for diagnosing prostate cancer. The invention also provides novel anti-STEAP-1 antibodies and uses thereof.

Compositions and methods for prostate cancer analysis

Growing community of inventors

South San Francisco, CA, United States of America

Mark Lackner